Harrison, C N
,
Vannucchi, A M
Kiladjian, J-J
Al-Ali, H K
Gisslinger, H
Knoops, L
Cervantes, F
Jones, M M
Sun, K
McQuitty, M
Stalbovskaya, V
Gopalakrishna, P
Barbui, T
Article History
Received: 10 March 2016
Revised: 5 May 2016
Accepted: 12 May 2016
First Online: 23 May 2016
Competing interests
: CNH has received research support from Novartis, Cell Therapeutics, Gilead and Baxaltra through the institution; has received personal fees from Novartis, Shire, Gilead and Baxaltra; and has received grant and non-financial support from Novartis outside the submitted work. AMV has received grant and personal fees from Novartis during the conduct of the study. J-JK has received travel grant, and research funding paid to the institution from Novartis; has acted as a consultant to Novartis and Incyte. HKA-A has received research funding from Novartis and Celgene; acted as a consultant to Novartis; and has received honoraria from Novartis and Celgene. HG has received honoraria from Novartis, Celgene and AOP Orphan Pharmaceuticals; and has two licensed patents: EP 13.18.6939.8 and 13.18.4632.1. FC has received personal fees from Novartis, CTI-Baxter and Sanofi. MMJ and KS are employees of Incyte. MM and VS are employees of and own stock in Novartis. PG is an employee of Novartis.